中国医学创新
中國醫學創新
중국의학창신
MEDICAL INNOVATION OF CHINA
2015年
25期
69-72
,共4页
胡国强%向阳%方军%杨力%冷芳%叶长根%叶家润
鬍國彊%嚮暘%方軍%楊力%冷芳%葉長根%葉傢潤
호국강%향양%방군%양력%랭방%협장근%협가윤
脂肪肝%非酒精性%胰岛素抵抗%吡格列酮%二甲双胍%代谢综合征
脂肪肝%非酒精性%胰島素牴抗%吡格列酮%二甲雙胍%代謝綜閤徵
지방간%비주정성%이도소저항%필격렬동%이갑쌍고%대사종합정
Fatty liver%Non-alcoholic%Insulin resistance%Pioglitazone%Metformin%Metabolic syndrome
目的：探讨吡格列酮联合二甲双胍治疗非酒精性脂肪性肝病的疗效。方法：将非酒精性脂肪性肝病患者70例按随机双盲法分治疗组和对照组各35例，治疗组使用吡格列酮联合二甲双胍，比较两组疗效。结果：3个月时，两组的观察指标均有改善，虽治疗组更明显，但差异无统计学意义（P>0.05）；6个月时，治疗组ALT、GGT、TG、HOMA-IR及疗效与对比组比较，差异有统计学意义（P<0.05）。结论：吡格列酮联合二甲双胍治疗NAFLD安全、有效，值得临床推广应用。
目的：探討吡格列酮聯閤二甲雙胍治療非酒精性脂肪性肝病的療效。方法：將非酒精性脂肪性肝病患者70例按隨機雙盲法分治療組和對照組各35例，治療組使用吡格列酮聯閤二甲雙胍，比較兩組療效。結果：3箇月時，兩組的觀察指標均有改善，雖治療組更明顯，但差異無統計學意義（P>0.05）；6箇月時，治療組ALT、GGT、TG、HOMA-IR及療效與對比組比較，差異有統計學意義（P<0.05）。結論：吡格列酮聯閤二甲雙胍治療NAFLD安全、有效，值得臨床推廣應用。
목적：탐토필격렬동연합이갑쌍고치료비주정성지방성간병적료효。방법：장비주정성지방성간병환자70례안수궤쌍맹법분치료조화대조조각35례，치료조사용필격렬동연합이갑쌍고，비교량조료효。결과：3개월시，량조적관찰지표균유개선，수치료조경명현，단차이무통계학의의（P>0.05）；6개월시，치료조ALT、GGT、TG、HOMA-IR급료효여대비조비교，차이유통계학의의（P<0.05）。결론：필격렬동연합이갑쌍고치료NAFLD안전、유효，치득림상추엄응용。
Objective: To discuss the safety and effectiveness of pioglitazone combined metformin in the treatment of non-alcoholic fatty liver disease (NAFLD).Method: 70 NAFLD patients were randomly divided into two groups, treatment group and control group, each group contained 35 cases, ALT, GGT, TG, HOMA-IR, BMI were compared between the two groups.Result: At the end of the 3rd month, the parameters were all improved but had no statistical difference (P>0.05). At the end of the 6th month, ALT, TG, HOMA-IR and effectiveness of the treatment group was much better than that of the control group, the differences were significant (P<0.O5).Conclusion: Pioglitazone combined metformin is safe and effective in the treatment of NAFLD.
